Completed
Phase 3
Age: 25Years - 70Years
All Genders
ID00461617
Multicentre, Double-Dummy, Randomized, Double-Blind Comparison Between Mitiglinide and Nateglinide in the Patients With Type 2 Diabetes
Led by Kissei Pharmaceutical Co., Ltd. · Updated on 2008-10-21
291
Participants Needed
N/A
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.
CONDITIONS
Brief Title
Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients
Who Can Participate
Age: 25Years - 70Years
All Genders
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes patients with inadequate control of blood glucose with diet and/or exercise therapy
Exclusion Criteria:
- Type 1 diabetes patients
- Patients who require treatment with insulin
- Patients with severe diabetic complications (neuropathy, retinopathy or nephropathy)
- Patients with severe ketosis, diabetic coma or precoma
- Patients complicated with severe hepatic diseases
- Patients complicated with severe renal diseases
- Patients complicated with severe hypertension
- Patients complicated with severe cardiac disease
- Pregnant women or women possible to be pregnant, nursing women, or women who want to become pregnant during the study period
Trial Site Locations
Site Locations not provided
Location information for this trial is currently unavailable.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here